Table 1. . Compound description.

Group	Compound	Main indication	Mechanism	Research phase in GBM treatment	Table S2 correlation no.
High potency	Palbociclib	Breast cancer	CDK inhibitor (CDK4/6)	Clinical trial	1
	Trihexyphenidyl	Parkinson's disease	Anticholinergic	None	2
	Clonidine	Arterial hypertension	Central alpha-adrenoceptor agonist	Pre-clinical	3
	Nilotinib	Leukemia and Philadelphia positive chronic myeloid	BCR/ABL tyrosine kinase inhibitor	Clinical trial	4
	Homatropine	Mydriasis induction	Anticholinergic	None	5
	Doxorubicin	Multiple types of cancers	Anthracycline, topo isomerase 2 inhibitor	Clinical trial	6
	Brexpiprazole	Psychosis	Serotonin-dopamine activity modulator	Pre-clinical	7
	Dasatinib	Leukemia, Philadelphia positive accute and chronic	Tyrosine kinase inhibitor, SRC-family	Clinical trial	8
	Nintedanib	Lung cancer	FGFR and VEGFR protein inhibitor	Clinical trial	9
Intermediate Potency	Vinblastine	Multiple types of cancers	Antimicrotubule	Clinical trial	10
	Imiquimod	Skin cancer	Immune response modifier	Clinical trial (indirect*)	11
	Phenoxybenzamine	Arterial hypertension	Alpha-adrenoceptor blocker	Pre-clinical	12
	Rizatriptan	Migraine	Serotonin agonist	None	13
	Letrozole	Breast cancer	Aromatase inhibitor	Pre-clinical	14
	Divalproex	Psychosis/epilepsy	GABA agonist/histone deacetylase inhibitor	Pre-clinical	15
	Regorafenib	Multiple types of cancers	VEGFR protein inhibitor	Pre-clinical	16
	Everolimus	Multiple types of cancers	mTOR inhibitor	Clinical trial	17
	Paclitaxel	Multiple types of cancers	Antimicrotubule	Pre-clinical	18
	Romidepsin	Leukemia	Histone deacetylase inhibitor	Clinical trial	19
	Topotecan	Multiple types of cancers	Topoisomerase 1 inhibitor	Pre-clinical	20
	Gefitinib	Lung cancer	EGFR inhibitor	Pre-clinical	21
	Temozolomide	Glioblastoma	Alkylate/methylate DNA	Clinical use	22